Akero Therapeutics, Inc. — Director's Dealing 2021

Jan 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2021-01-07

Reporting Person: Cheng Andrew (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-07	Common Stock	M	20000	$0.615	Acquired	362989	Direct
2020-12-31	Common Stock	G	3000	—	Disposed	359989	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-07	Employee Stock Option (Right to Buy)	$0.615	M	20000	Disposed	2028-09-07	Common Stock (20000)	Direct

Footnotes

F1: The shares reported in this transaction represent a bona fide charitable gift to a donor advised fund. The Reporting Person does not have any pecuniary interest in the fund's assets.

F2: 25% of this option vested and became exercisable on September 1, 2019, with the remainder vesting in 36 equal monthly installments thereafter.